Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibrosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis - Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape. Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Fibrosis - Overview 8 Fibrosis - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Fibrosis - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 22 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Fibrosis - Companies Involved in Therapeutics Development 29 Acceleron Pharma Inc 29 Aelis Farma SAS 29 Allakos Inc 30 Anima Biotech Ltd 30 Bristol-Myers Squibb Company 31 Calypso Biotech SA 31 Complexa Inc 32 Encycle Therapeutics Inc 32 F. Hoffmann-La Roche Ltd 33 Five Prime Therapeutics Inc 33 Genfit SA 34 GlycoMimetics Inc 34 Hanmi Pharmaceuticals Co Ltd 35 iBio Inc 35 Immunomet Therapeutics Inc 36 Inception Sciences Inc 36 Insmed Inc 37 Inventiva 37 Ironwood Pharmaceuticals Inc 38 Isarna Therapeutics GmbH 38 Lycera Corp 39 Neumedicines Inc 39 Novartis AG 40 Palatin Technologies Inc 40 Ribomic Inc 41 Scholar Rock Inc 41 SciFluor Life Sciences LLC 42 SK Chemicals Co Ltd 42 UCB SA 43 VivaCell Biotechnology Espana SL 43 Fibrosis - Drug Profiles 44 ACE-2798 - Drug Profile 44 AEF-0118 - Drug Profile 45 AK-002 - Drug Profile 46 Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile 48 CALY-001 - Drug Profile 49 CWHM-12 - Drug Profile 50 elafibranor - Drug Profile 51 G-XXX - Drug Profile 60 IB-DMD - Drug Profile 61 IBIOCFB-03 - Drug Profile 62 IM-156 - Drug Profile 64 INS-1007 - Drug Profile 65 ISTH-1106 - Drug Profile 66 IW-1701 - Drug Profile 67 IW-1973 - Drug Profile 68 LYC-53976 - Drug Profile 70 Monoclonal Antibodies for Fibrosis - Drug Profile 71 Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile 72 Monoclonal Antibody 2 for Fibrosis - Drug Profile 73 Monoclonal Antibody for Fibrotic Scar - Drug Profile 74 Monoclonal Antibody to Activate BMP7 for Fibrosis - Drug Profile 75 NCE-401 - Drug Profile 76 Neumomir - Drug Profile 77 NMIL-121 - Drug Profile 78 OCX-063 - Drug Profile 82 PAT-048 - Drug Profile 83 PL-5028 - Drug Profile 84 PRI-724 - Drug Profile 85 Proteins for Central Nervous System Disorders and Fibrosis - Drug Profile 87 RBM-003 - Drug Profile 88 RBM-007 - Drug Profile 89 Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile 90 Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 91 RG-6125 - Drug Profile 92 Small Molecule for Fibrosis - Drug Profile 94 Small Molecule for Fibrosis - Drug Profile 95 Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 96 Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile 97 Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile 98 Small Molecules for Fibrosis - Drug Profile 99 Small Molecules for Fibrosis - Drug Profile 100 Small Molecules for Fibrosis - Drug Profile 101 Small Molecules for Fibrosis - Drug Profile 102 Small Molecules for Fibrosis - Drug Profile 103 Small Molecules for Fibrosis - Drug Profile 104 Small Molecules for Fibrosis and Inflammatory Diseases - Drug Profile 105 Small Molecules for Fibrosis and Oncology - Drug Profile 106 Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 107 Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile 108 Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 109 Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology - Drug Profile 110 Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile 111 SRI-31277 - Drug Profile 112 ST-2001 - Drug Profile 113 Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology - Drug Profile 114 VCE-0048 - Drug Profile 115 X-165 - Drug Profile 116 XOMA-089 - Drug Profile 117 Fibrosis - Dormant Projects 118 Fibrosis - Product Development Milestones 120 Featured News & Press Releases 120 Appendix 127 Methodology 127 Coverage 127 Secondary Research 127 Primary Research 127 Expert Panel Validation 127 Contact Us 127 Disclaimer 128
List of Tables
Number of Products under Development for Fibrosis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Fibrosis - Pipeline by Acceleron Pharma Inc, H1 2017 Fibrosis - Pipeline by Aelis Farma SAS, H1 2017 Fibrosis - Pipeline by Allakos Inc, H1 2017 Fibrosis - Pipeline by Anima Biotech Ltd, H1 2017 Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2017 Fibrosis - Pipeline by Calypso Biotech SA, H1 2017 Fibrosis - Pipeline by Complexa Inc, H1 2017 Fibrosis - Pipeline by Encycle Therapeutics Inc, H1 2017 Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Fibrosis - Pipeline by Five Prime Therapeutics Inc, H1 2017 Fibrosis - Pipeline by Genfit SA, H1 2017 Fibrosis - Pipeline by GlycoMimetics Inc, H1 2017 Fibrosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 Fibrosis - Pipeline by iBio Inc, H1 2017 Fibrosis - Pipeline by Immunomet Therapeutics Inc, H1 2017 Fibrosis - Pipeline by Inception Sciences Inc, H1 2017 Fibrosis - Pipeline by Insmed Inc, H1 2017 Fibrosis - Pipeline by Inventiva, H1 2017 Fibrosis - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017 Fibrosis - Pipeline by Lycera Corp, H1 2017 Fibrosis - Pipeline by Neumedicines Inc, H1 2017 Fibrosis - Pipeline by Novartis AG, H1 2017 Fibrosis - Pipeline by Palatin Technologies Inc, H1 2017 Fibrosis - Pipeline by Ribomic Inc, H1 2017 Fibrosis - Pipeline by Scholar Rock Inc, H1 2017 Fibrosis - Pipeline by SciFluor Life Sciences LLC, H1 2017 Fibrosis - Pipeline by SK Chemicals Co Ltd, H1 2017 Fibrosis - Pipeline by UCB SA, H1 2017 Fibrosis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017 Fibrosis - Dormant Projects, H1 2017 Fibrosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.